These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 23108522)
1. Rivaroxaban in acute coronary syndromes and atrial fibrillation: rivaroxaban shown to reduce cardiovascular deaths in STEMI patients. Aalbers J Cardiovasc J Afr; 2012 Oct; 23(9):525-6. PubMed ID: 23108522 [No Abstract] [Full Text] [Related]
2. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes. Reddy P; Giugliano RP J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084 [TBL] [Abstract][Full Text] [Related]
3. Raft of rivaroxaban good news from the USA, implications for South African clinical practice. Cardiovasc J Afr; 2011; 22(6):345-6. PubMed ID: 22159327 [No Abstract] [Full Text] [Related]
4. Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome. Ahrens I; Bode C Future Cardiol; 2012 Jul; 8(4):533-41. PubMed ID: 22871192 [TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban and other novel anticoagulants for stroke prevention in atrial fibrillation: time to embrace the future. Rajappan K Heart; 2013 Mar; 99(6):361-2. PubMed ID: 23024007 [No Abstract] [Full Text] [Related]
6. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398 [TBL] [Abstract][Full Text] [Related]
7. [Rivaroxaban in prevention of stroke in patients with atrial fibrillation]. Simonyi G; Medvegy M Ideggyogy Sz; 2012 Nov; 65(11-12):365-8. PubMed ID: 23289170 [TBL] [Abstract][Full Text] [Related]
8. Dissolution of the left atrial appendage thrombus with rivaroxaban therapy. Takasugi J; Yamagami H; Okata T; Toyoda K; Nagatsuka K Cerebrovasc Dis; 2013; 36(4):322-3. PubMed ID: 24192983 [No Abstract] [Full Text] [Related]
9. [Prevention and therapy of thromboembolism: rivaroxaban - better outcome - risk profile as standard therapy]. MMW Fortschr Med; 2013 Sep; 155(15):56-7. PubMed ID: 24224377 [No Abstract] [Full Text] [Related]
10. Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial. Paikin JS; Manolakos JJ; Eikelboom JW Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):965-72. PubMed ID: 23030284 [TBL] [Abstract][Full Text] [Related]
11. European Society of Cardiology congress 2011. Cardiovasc J Afr; 2011; 22(5):287-8, 291-2. PubMed ID: 21983959 [No Abstract] [Full Text] [Related]
12. FDA advisory decision highlights some problems inherent in pragmatic trials. Mitka M JAMA; 2011 Nov; 306(17):1851-2. PubMed ID: 22045759 [No Abstract] [Full Text] [Related]
13. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Mantha S; Ansell J Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145 [TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban equals warfarin treatment in atrial fibrillation patients at high risk of stroke. Aalbers J Cardiovasc J Afr; 2010; 21(6):342-3. PubMed ID: 21135986 [No Abstract] [Full Text] [Related]
15. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583 [TBL] [Abstract][Full Text] [Related]
16. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51). Krantz MJ; Kaul S J Am Coll Cardiol; 2013 Aug; 62(9):777-81. PubMed ID: 23747777 [TBL] [Abstract][Full Text] [Related]
17. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Ahrens I; Lip GY; Peter K Thromb Haemost; 2011 Apr; 105(4):574-8. PubMed ID: 21225102 [No Abstract] [Full Text] [Related]
18. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban. Morell J; Sullivan B; Khalabuda M; McBride BF J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518 [TBL] [Abstract][Full Text] [Related]
19. [Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?]. Silber S; Helms TM; Garlichs C; Arntz HR; Weil J; Ince H; Klingenheben T; Hoffmann S; Boudriot E; Steiger H; Zugck C Dtsch Med Wochenschr; 2011 Apr; 136(15):782-5. PubMed ID: 21432747 [No Abstract] [Full Text] [Related]
20. Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease. Morales-Vidal S; Schneck MJ; Flaster M; Biller J Expert Rev Neurother; 2012 Feb; 12(2):179-89; quiz 190. PubMed ID: 22288673 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]